New drug duo aims to stop deadly skin Cancer's return
NCT ID NCT02656706
Summary
This study is testing whether a combination of two immunotherapy drugs, nivolumab and ipilimumab, can help prevent melanoma from returning in patients who have had it surgically removed but are at high risk of it coming back. The treatment is given for six months after surgery. The main goals are to see if the drug combination is safe and if it helps patients live longer without their cancer returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rhode Island Hospital and The Miriam Hospital
Providence, Rhode Island, 02903/02906, United States
Conditions
Explore the condition pages connected to this study.